Understanding the Cali Fund: new expectations for biotech’s use of DSI

Questions? Contact the team.

Linda Bedenik

Senior Policy and Public Affairs Manager, BIA

Global DSI rules have changed – is your company ready?

Join us for an insightful webinar explaining the landmark decision made at COP16 to establish a multilateral benefit-sharing mechanism for the use of Digital Sequence Information (DSI) and the Cali Fund. This pivotal development has significant implications for biotech and life sciences companies utilising (non-human) Digital Sequence Information (DSI) in their operations.

While there remains a lack of clarity surrounding certain aspects of the decision, the Cali Fund is already operational, and companies using DSI are expected to contribute to it now. Join our webinar to gain crucial insights into what this means for your business, including the expectations of UK biotech companies to contribute to the Fund.